Piper Sandler analyst David Westenberg lowered the firm’s price target on Quest Diagnostics (DGX) to $190 from $200 following quarterly results. The firm keeps a Neutral rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics: Strong Volume Growth and Strategic Partnerships Drive Buy Rating
- Quest Diagnostics price target raised to $185 from $180 at Evercore ISI
- Quest Diagnostics price target raised to $191 from $182 at Morgan Stanley
- Quest Diagnostics price target raised to $180 from $175 at UBS
- Quest Diagnostics price target raised to $192 from $190 at Truist